These data provide evidence in support of a leukemogenic role for BCR-JAK2 fusion in myeloproliferative disorders, including CML, and complements data provided by the first case report by Griesinger et al. [11]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.